| Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey R Zeiser, A Burchert, C Lengerke, M Verbeek, K Maas-Bauer, ... Leukemia 29 (10), 2062-2068, 2015 | 628 | 2015 |
| Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2 … U Platzbecker, JM Middeke, K Sockel, R Herbst, D Wolf, CD Baldus, ... The Lancet Oncology 19 (12), 1668-1679, 2018 | 323 | 2018 |
| CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome F Taube, JA Georgi, M Kramer, S Stasik, JM Middeke, C Röllig, U Krug, ... Blood, The Journal of the American Society of Hematology 139 (1), 87-103, 2022 | 124 | 2022 |
| Mesenchymal stromal cells for treatment of acute steroid-refractory graft versus host disease: clinical responses and long-term outcome F von Dalowski, M Kramer, M Wermke, R Wehner, C Röllig, N Alakel, ... Stem Cells 34 (2), 357-366, 2016 | 121 | 2016 |
| MRI-based liver iron content predicts for nonrelapse mortality in MDS and AML patients undergoing allogeneic stem cell transplantation M Wermke, A Schmidt, JM Middeke, K Sockel, M von Bonin, ... Clinical Cancer Research 18 (23), 6460-6468, 2012 | 98 | 2012 |
| Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia … K Sockel, M Bornhaeuser, E Mischak-Weissinger, R Trenschel, ... Haematologica 97 (9), e34, 2012 | 89 | 2012 |
| Comparison between 5-azacytidine treatment and allogeneic stem-cell transplantation in elderly patients with advanced MDS according to donor availability (VidazaAllo Study) N Kröger, K Sockel, C Wolschke, W Bethge, RF Schlenk, D Wolf, ... Journal of Clinical Oncology 39 (30), 3318-3327, 2021 | 86 | 2021 |
| CHIP and hips: clonal hematopoiesis is common in patients undergoing hip arthroplasty and is associated with autoimmune disease JS Hecker, L Hartmann, J Rivière, MC Buck, M van der Garde, ... Blood, The Journal of the American Society of Hematology 138 (18), 1727-1732, 2021 | 84 | 2021 |
| Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse K Sockel, M Wermke, J Radke, A Kiani, M Schaich, M Bornhäuser, ... Haematologica 96 (10), 1568, 2011 | 84 | 2011 |
| Deep learning detects acute myeloid leukemia and predicts NPM1 mutation status from bone marrow smears JN Eckardt, JM Middeke, S Riechert, T Schmittmann, AS Sulaiman, ... Leukemia 36 (1), 111-118, 2022 | 75 | 2022 |
| Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT N Kröger, G Sbianchi, T Sirait, C Wolschke, D Beelen, J Passweg, ... Leukemia 35 (12), 3551-3560, 2021 | 66 | 2021 |
| Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia C Rautenberg, F Stölzel, C Röllig, M Stelljes, V Gaidzik, M Lauseker, ... Blood Cancer Journal 11 (10), 164, 2021 | 49 | 2021 |
| The prevalence of extramedullary acute myeloid leukemia detected by 18FDG-PET/CT: final results from the prospective PETAML trial F Stölzel, T Lüer, S Löck, S Parmentier, F Kuithan, M Kramer, NS Alakel, ... Haematologica 105 (6), 1552, 2019 | 48 | 2019 |
| Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents AS Kubasch, F Schulze, A Giagounidis, KS Götze, J Krönke, K Sockel, ... Leukemia 34 (4), 1182-1186, 2020 | 47 | 2020 |
| Deep learning identifies acute promyelocytic leukemia in bone marrow smears JN Eckardt, T Schmittmann, S Riechert, M Kramer, AS Sulaiman, K Sockel, ... BMC cancer 22 (1), 201, 2022 | 46 | 2022 |
| Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial JM Middeke, R Herbst, S Parmentier, G Bug, M Hänel, G Stuhler, ... Leukemia 30 (2), 261-267, 2016 | 38 | 2016 |
| Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatment R Teipel, F Kroschinsky, M Kramer, T Kretschmann, K Egger-Heidrich, ... Blood Advances 6 (6), 1941-1946, 2022 | 36 | 2022 |
| Donor cell leukemia: evidence for multiple preleukemic clones and parallel long term clonal evolution in donor and recipient S Herold, M Kuhn, T Stange, U Platzbecker, J Radke, T Lange, K Sockel, ... Leukemia 31 (7), 1637-1640, 2017 | 36 | 2017 |
| Long-term efficacy and safety of luspatercept for anemia treatment in patients with lower-risk myelodysplastic syndromes: the phase II PACE-MDS study U Platzbecker, KS Götze, P Kiewe, U Germing, K Mayer, M Radsak, ... Journal of Clinical Oncology 40 (33), 3800-3807, 2022 | 31 | 2022 |
| Disease progression of WHIM syndrome in an international cohort of 66 pediatric and adult patients CB Geier, M Ellison, R Cruz, S Pawar, A Leiss-Piller, K Zmajkovicova, ... Journal of clinical immunology 42 (8), 1748-1765, 2022 | 29 | 2022 |
